Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's Wegovy® is one of two branded, FDA approved, GLP-1s. On February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved.

Novo Nordisk's Wegovy® is one of two branded, FDA approved, GLP-1s. On February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved.

Novo Nordisk's Wegovy® is one of two branded, FDA approved, GLP-1s. On February 21, 2025, the FDA determined that the semaglutide product shortage had been resolved.